Oncosil Limited
Climate Impact & Sustainability Data (FY18 to FY22e)
Reporting Period: FY18 to FY22e
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Medical Community is slow to adopt new therapy
- Funding – Oncosil is likely to require further equity in order to complete the clinical program
- Clinical Risk – Success in the clinic is required in order for the product to be marketed in the US. There is no guarantee that results from previous studies will be repeated in a broader, multi centre trial.
- Other commercial risks - The validity of patents which protect the future income stream from OncoSil are yet to be tested. In addition, normal commercial risk relating to reliance on suppliers also apply.
- Oncosil Medical Ltd does not manufacture the Oncosil product and is entirely depended on a small number of hi-tech manufacturers for supply to its customer base.
- OncoSil is a highly toxic material. Its manufacture, storage, transport and use are each subject to regulatory requirements.
Mitigation Strategies
- The company will be required to conduct at least 1 large pivotal study in the US in order to gain approval.
- Ideally OSL will generate cash from sales in Australia and Europe to assist with the funding of the US study.